Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.

Casey DL, Wexler LH, Pitter KL, Samstein RM, Slotkin EK, Wolden SL.

Clin Cancer Res. 2019 Nov 7. pii: clincanres.2631.2019. doi: 10.1158/1078-0432.CCR-19-2631. [Epub ahead of print]

PMID:
31699828
2.

Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.

Lee M, Samstein RM, Valero C, Chan TA, Morris LGT.

Hum Vaccin Immunother. 2019 Jul 30:1-4. doi: 10.1080/21645515.2019.1631136. [Epub ahead of print]

PMID:
31361563
3.

In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.

Khalil DN, Suek N, Campesato LF, Budhu S, Redmond D, Samstein RM, Krishna C, Panageas KS, Capanu M, Houghton S, Hirschhorn D, Zappasodi R, Giese R, Gasmi B, Schneider M, Gupta A, Harding JJ, Moral JA, Balachandran VP, Wolchok JD, Merghoub T.

J Clin Invest. 2019 Jul 22;129(8):3435-3447. doi: 10.1172/JCI128562. eCollection 2019 Jul 22.

4.

Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response.

Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, Ramaswamy AT, Durham JN, Bartlett B, Ma X, Srivastava R, Middha S, Zehir A, Hechtman JF, Morris LG, Weinhold N, Riaz N, Le DT, Diaz LA Jr, Chan TA.

Science. 2019 May 3;364(6439):485-491. doi: 10.1126/science.aau0447.

5.

Immunogenic neoantigens derived from gene fusions stimulate T cell responses.

Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, Makarov V, Hoen D, Dalin MG, Wexler L, Ghossein R, Katabi N, Nadeem Z, Cohen MA, Tian SK, Robine N, Arora K, Geiger H, Agius P, Bouvier N, Huberman K, Vanness K, Havel JJ, Sims JS, Samstein RM, Mandal R, Tepe J, Ganly I, Ho AL, Riaz N, Wong RJ, Shukla N, Chan TA, Morris LGT.

Nat Med. 2019 May;25(5):767-775. doi: 10.1038/s41591-019-0434-2. Epub 2019 Apr 22.

6.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
7.

The DNA damage response in immunotherapy and radiation.

Samstein RM, Riaz N.

Adv Radiat Oncol. 2018 Oct 23;3(4):527-533. doi: 10.1016/j.adro.2018.08.017. eCollection 2018 Oct-Dec. Review.

8.

An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models.

Markovsky E, Budhu S, Samstein RM, Li H, Russell J, Zhang Z, Drill E, Bodden C, Chen Q, Powell SN, Merghoub T, Wolchok JD, Humm J, Deasy JO, Haimovitz-Friedman A.

Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):697-708. doi: 10.1016/j.ijrobp.2018.10.009. Epub 2018 Oct 18.

PMID:
30342090
9.

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA.

Science. 2018 Feb 2;359(6375):582-587. doi: 10.1126/science.aao4572. Epub 2017 Dec 7.

10.

Dissecting microsatellite instability in colorectal cancer: one size does not fit all.

Samstein RM, Chan TA.

Genome Med. 2017 May 24;9(1):45. doi: 10.1186/s13073-017-0438-9.

11.

Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.

Samstein RM, Carvajal RD, Postow MA, Callahan MK, Shoushtari AN, Patel SG, Lee NY, Barker CA.

Head Neck. 2016 Sep;38(9):1310-7. doi: 10.1002/hed.24435. Epub 2016 Apr 4.

12.

Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy.

Samstein RM, Ho AL, Lee NY, Barker CA.

J Skin Cancer. 2014;2014:284582. doi: 10.1155/2014/284582. Epub 2014 Jul 21.

13.

Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells.

Arvey A, van der Veeken J, Samstein RM, Feng Y, Stamatoyannopoulos JA, Rudensky AY.

Nat Immunol. 2014 Jun;15(6):580-587. doi: 10.1038/ni.2868. Epub 2014 Apr 13.

14.

Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification.

Samstein RM, Arvey A, Josefowicz SZ, Peng X, Reynolds A, Sandstrom R, Neph S, Sabo P, Kim JM, Liao W, Li MO, Leslie C, Stamatoyannopoulos JA, Rudensky AY.

Cell. 2012 Sep 28;151(1):153-66. doi: 10.1016/j.cell.2012.06.053.

15.

Transcription factor Foxp3 and its protein partners form a complex regulatory network.

Rudra D, deRoos P, Chaudhry A, Niec RE, Arvey A, Samstein RM, Leslie C, Shaffer SA, Goodlett DR, Rudensky AY.

Nat Immunol. 2012 Oct;13(10):1010-9. doi: 10.1038/ni.2402. Epub 2012 Aug 26.

16.

Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict.

Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY.

Cell. 2012 Jul 6;150(1):29-38. doi: 10.1016/j.cell.2012.05.031.

17.

Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation.

Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller W, Rudensky AY.

Immunity. 2011 Apr 22;34(4):566-78. doi: 10.1016/j.immuni.2011.03.018.

18.

CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner.

Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, Rudensky AY.

Science. 2009 Nov 13;326(5955):986-91. doi: 10.1126/science.1172702. Epub 2009 Oct 1.

19.

Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation.

Goldberg GL, King CG, Nejat RA, Suh DY, Smith OM, Bretz JC, Samstein RM, Dudakov JA, Chidgey AP, Chen-Kiang S, Boyd RL, van den Brink MR.

J Immunol. 2009 May 1;182(9):5846-54. doi: 10.4049/jimmunol.0801458.

20.

The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles.

Samstein RM, Perica K, Balderrama F, Look M, Fahmy TM.

Biomaterials. 2008 Feb;29(6):703-8. Epub 2007 Nov 19.

PMID:
18006053
21.

Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells.

Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T.

Nat Med. 2006 Jun;12(6):657-64. Epub 2006 May 21.

PMID:
16715089
22.

Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting.

Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W.

Biomaterials. 2005 Oct;26(28):5727-36. Epub 2005 Apr 18.

PMID:
15878378

Supplemental Content

Loading ...
Support Center